Materiały źródłowe

• #1 Bexsero – Treatment for Meningitis B (MenB) Disease – Clinical Trials Arena

  https://www.clinicaltrialsarena.com/marketdata/bexsero-multicomponent-meningococcal-serogroup-b-vaccine/

  Bexsero is a vaccine indicated for the treatment of meningococcal group B (MenB) disease. It is the first and the only Men B vaccine for the protection of all age groups against the disease. […] Novartis received a breakthrough therapy designation for Bexsero from the FDA in April 2014. […] Bexsero has received a Breakthrough Therapy designation from the US FDA. […] Vaccines targeting meningococcal disease caused by serogroups A, C, W135 and Y are already available in the market. Treatment for MenB, however, still remains unavailable. The market for MenB treatment therefore represents huge potential.

• #1

  https://www.meningitis.org/meningitis/vaccine-information/meningococcal-group-b-vaccine

  Meningococcal vaccines protect against disease caused by meningococcal bacteria. […] The vaccines that protect against meningococcal group B (MenB) are protein vaccines. These vaccines contain proteins found on the surface of the bacteria. […] The MenB vaccine provides protection against meningococcal disease, but doesn’t stop you from carrying the bacteria. […] Vaccination against meningococcal meningitis is also recommended if you’re travelling to areas at risk. […] Meningococcal vaccines have saved many lives. […] Vaccination with conjugate meningococcal vaccines also protects the wider population from meningococcal disease. […] Vaccination is the best way to protect against it. […] Meningococcal vaccines are effective at preventing meningococcal disease. […] Meningococcal vaccines are not live vaccines. They cannot cause meningococcal meningitis.

• #1 Meningitis B: Symptoms, causes, treatment, and prevention

  https://www.medicalnewstoday.com/articles/meningitis-b

  Meningitis B is a medical emergency, and healthcare professionals will treat it as soon as possible using antibiotics. […] Doctors may also treat those in contact with someone with meningitis B as a preventative measure. […] Meningitis B vaccines include Bexsero and Trumenba. […] Those aged 16-23 years can get the MenB vaccine, as well as those who are at an increased risk of meningococcal disease, including: those at risk due to an outbreak, those who have a damaged spleen or those without a spleen, including those with sickle cell disease, those with complement component deficiency, which is a rare condition that affects the immune system, those taking complement inhibitor drugs, such as eculizumab or ravulizumab, microbiologists who work with N. meningitidis. […] The side effects of meningococcal vaccines are mild and present in more than half of those who are vaccinated.

• #1 A physician’s guide to the 2-dose schedule of MenB-FHbp vaccine

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6930067/

  MenB vaccines were first licensed in the United States in 2014 under the US Food and Drug Administration (FDA) accelerated approval process in response to two US college-based MenB outbreaks in 2013. Two products are currently approved for use in adolescents and young adults 1025 y of age: MenB-FHbp and MenB-4C (Bexsero; GlaxoSmithKline Vaccines, Srl, Siena, Italy). MenB-FHbp is composed of two recombinant lipidated FHbp variants, one each from subfamily A and subfamily B. MenB-FHbp is administered in either a 2-dose schedule (at 0 and 6 months) to healthy individuals who are not at increased disease risk or a tailored 3-dose schedule (at 0, 12, and 6 months) for those at increased risk of meningococcal disease and in response to MenB disease outbreaks, to provide earlier protection and maximize short-term immunogenicity.

• #1 GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age | GSK

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-meningitis-b-vaccine-bexsero-receives-breakthrough-therapy-designation-from-us-fda-for-prevention-of-invasive-meningococcal-disease-in-children-2-10-years-of-age/

  GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its meningitis B vaccine Bexsero for the development of the vaccine in the prevention of Invasive Meningococcal Disease (IMD) caused by serogroup B in children 2-10 years of age. […] Bexsero is the first vaccine in the world to receive the Breakthrough Therapy Designation (BTD) twice. […] This designation emphasises the importance of tackling big scientific challenges like meningitis B and breaking new ground in disease prevention through approaches like reverse vaccinology. […] Thirty-five percent of all meningitis B cases in the US occur in children under 11 years old. This designation is an important step forward in meningococcal prevention and extending the protection provided by this vaccine to a vulnerable age group in the US.

• #1 Meningococcal B vaccine – what you need to know: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/007659.htm

  Meningococcal B vaccine can help protect against meningococcal disease caused by serogroup B. A different meningococcal vaccine is available that can help protect against serogroups A, C, W, and Y. […] For best protection, more than 1 dose of a meningococcal B vaccine is needed. There are two meningococcal B vaccines available. The same vaccine must be used for all doses. […] Meningococcal B vaccines are recommended for people 10 years or older who are at increased risk for serogroup B meningococcal disease, including: […] These vaccines may also be given to anyone 16 through 23 years old to provide short-term protection against most strains of serogroup B meningococcal disease, based on discussions between the patient and health care provider. […] Meningococcal B vaccination should be postponed for pregnant women unless the woman is at increased risk and, after consultation with her health care provider, the benefits of vaccination are considered to outweigh the potential risks.

• #1 Ask The Experts About Vaccines: Meningococcal B | Immunize.org

  https://www.immunize.org/ask-experts/topic/menb/

  MenB vaccines were approved based on the serologic response to the vaccine. Because meningococcal B disease is so rare, no data are available on vaccine effectiveness against clinical disease or duration of protection against clinical disease. Short term protection refers to the known duration of the antibody response. Available data indicate that protective antibody levels wane in most recipients within 12 years of completion of the primary series. Antibody levels rise sharply within 1-2 weeks of a booster dose. […] MenB is routinely recommended for these groups: People age 10 years and older who have functional or anatomic asplenia (including sickle cell disease), People age 10 years and older who have persistent complement component deficiency (an immune system disorder) or who take a complement inhibitor (examples include eculizumab [Soliris], ravulizumab [Ultomiris], and sutimlimab [Sanofi]), People age 10 years and older who are exposed during an outbreak caused by serogroup B, Microbiologists who work with meningococcal isolates in a laboratory.

• #1 Meningococcal disease | The Australian Immunisation Handbook

  https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/meningococcal-disease

  People with medical conditions specified in List. Specified medical conditions associated with increased risk of invasive meningococcal disease are recommended to receive MenACWY and MenB vaccines. […] Laboratory workers who frequently handle Neisseria meningitidis are recommended to receive MenACWY and MenB vaccines.

• #1

  https://www.nhs.uk/conditions/meningitis/

  MenB vaccine offered to babies aged 8 weeks, followed by a second dose at 16 weeks and a booster at 1 year. […] Treatments include: antibiotics given directly into a vein. […] Bacterial meningitis usually needs to be treated in hospital for at least a week.

• #1 Meningitis | Student Health Center | Western Washington University

  https://studenthealth.wwu.edu/meningitis

  Based on the possibility of increased risk, students entering Western are advised to strongly consider the Meningococcal vaccine as a way to reduce their risk for potentially fatal Meningococcal disease. […] Two separate meningitis vaccines are necessary to be fully immunized against the disease: MenACWY and MenB. While many adolescents and young adults have received the MenACWY vaccine as part of their regular immunizations, few have received the MenB vaccine. […] Meningococcal disease strain B, commonly referred to as MenB, is the most common cause of bacterial meningitis on college campuses. The Centers for Disease Control and Prevention recommend being vaccinated against meningitis B. […] Make sure you have BOTH meningitis vaccines to fully protect yourself and those around you. […] The MenB vaccine is available at most pharmacies. Check with your health insurance carrier to see if it is covered.

• #1 Meningococcal vaccines: Canadian Immunization Guide – Canada.ca

  https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-13-meningococcal-vaccine.html

  MenB-fHBP may be administered concurrently with other vaccines in individuals 10 years of age and older. […] A study of Men-C-C vaccine demonstrated effectiveness in infants of 97% within one year of vaccination, decreasing to 68% after 1 year. […] Vaccine effectiveness of Men-C-ACYW-DT within 3 to 4 years of vaccination in adolescence is 80% to 85%; however, effectiveness wanes over time. […] Meningococcal vaccines are recommended for individuals at high risk of IMD including those with underlying medical conditions and those who are at increased risk of exposure. […] Individuals with increased risk of meningococcal disease because of underlying medical conditions include the following: persons with functional or anatomic asplenia or sickle cell disease, persons with congenital immunodeficiencies such as complement, properdin, factor D, combined T and B cell immunodeficiencies or primary antibody deficiencies, persons with acquired complement deficiency due to receipt of the terminal complement inhibitor eculizumab (Soliris) or ravulizumab (ULTOMIRIS), individuals with HIV, especially if it is perinatally acquired.

• #1 Meningococcemia Treatment & Management: Approach Considerations, Emergency Management of Meningococcal Infection, Pharmacologic Therapy

  https://emedicine.medscape.com/article/221473-treatment

  Specific categories of individuals at high risk for meningococcal disease include the following: Persistent complement component deficiencies, such as C3, C5C9, properdin, factor D, or factor H deficiencies, can increase the risk for meningococcal disease up to 10,000-fold. Patients with complement deficiencies may experience recurrent disease, and inherited disorders within families may also be affected, warranting consideration for testing for complement deficiency in individuals with meningococcal disease. […] The use of complement inhibitors, such as eculizumab (Soliris) and ravulizumab (Ultomiris), is associated with a substantially increased risk for meningococcal disease. Eculizumab use, in particular, has been linked to a significant incidence of meningococcal disease. Therefore, healthcare providers should consider antimicrobial prophylaxis for patients receiving complement inhibitors to mitigate the risk of infection.

• #1 Clinical Guidance for Managing Meningococcal Disease Risk in Patients Receiving Complement Inhibitor Therapy | Meningococcal | CDC

  https://www.cdc.gov/meningococcal/hcp/clinical-guidance/complement-inhibitor.html

  CDC recommends both MenACWY and MenB vaccines for people receiving a complement inhibitor. Ideally, complete or update meningococcal vaccination at least 2 weeks prior to administering the first dose of the complement inhibitor. However, patients can initiate complement inhibitor therapy before meningococcal vaccination has been completed if the risks for delaying complement inhibitor therapy outweigh the risks for developing meningococcal disease. […] Initial series: MenB vaccines require 3 doses. […] Booster doses: Administer a booster dose of MenB vaccine: 1 year after series completion, every 2 to 3 years thereafter, for the duration of complement inhibitor therapy. […] Targets: Serogroup B; cross protection against nongroupable N. meningitidis hasn’t been systematically assessed.

• #1 Vaccination Requirements | ULTOMIRIS® (ravulizumab-cwvz) | gMG

  https://ultomirishcp.com/gmg/vaccination-requirements

  Complete or update meningococcal vaccination (for serogroups A, C, W, Y and B) at least 2 weeks prior to administration of the first dose of ULTOMIRIS, per the current ACIP recommendations for patients receiving a complement inhibitor. […] Your patient must receive both MenACWY and MenB vaccine series. The vaccines may be administered during the same visit but at different injection sites. […] To help reduce the risk of meningococcal infections, the complete series for the MenACWY and MenB vaccines should be administered. […] Revaccinate patients in accordance with ACIP recommendations considering the duration of ULTOMIRIS therapy. […] Vaccination does not eliminate the risk of serious meningococcal infections, despite development of antibodies following vaccination. […] Patients receiving ULTOMIRIS are at increased risk for invasive disease caused by Neisseria meningitidis, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious meningococcal infections and evaluate immediately if infection is suspected.

• #1 Vaccine Update: ACIP Updates the Immunization Schedule Recommendations for Bexsero (MenB-4C) | Children’s Mercy Kansas City

  https://www.childrensmercy.org/health-care-providers/refer-or-manage-a-patient/connect-with-childrens-mercy/newsletter-the-link/2024/the-link—december-2024/vaccine-update-acip-updates-the-immunization-schedule-recommendations-for-bexsero-menb-4c/

  On Oct. 24, 2024, the Advisory Committee on Immunization Practices (ACIP) voted to revise the immunization schedule for Bexsero (MenB-4C). This recommendation aligns with the full product approval that the U.S. Food and Drug Administration granted Bexsero on Aug. 19, 2024. Following new immunogenicity data, the schedule recommendation was updated to provide the most optimal protection. […] Bexsero is a vaccine used to prevent invasive disease caused by Neisseria meningitidis serogroup B. Invasive disease from N. meningitidis serogroup B (MenB) can lead to meningitis, sepsis and death. […] The new recommendations are as follows: For healthy adolescents and young adults aged 16-23 years (preferred 16-18), meningococcal serogroup B vaccination is currently recommended with shared clinical decision-making.

• #1 Vaccine Update: ACIP Updates the Immunization Schedule Recommendations for Bexsero (MenB-4C) | Children’s Mercy Kansas City

  https://www.childrensmercy.org/health-care-providers/refer-or-manage-a-patient/connect-with-childrens-mercy/newsletter-the-link/2024/the-link—december-2024/vaccine-update-acip-updates-the-immunization-schedule-recommendations-for-bexsero-menb-4c/

  New Recommendation: Two-dose series at zero and six months. […] For persons aged 10 years at increased risk for serogroup B meningococcal disease (i.e., persons with anatomic or functional asplenia, complement component deficiencies, or complement inhibitor use; microbiologists routinely exposed to N. meningitidis isolates; and persons at increased risk during an outbreak). […] New Recommendation: Three-dose series at zero, one to two months, and six months. […] For both healthy adolescents and persons at increased risk who were vaccinated at zero and one month or later (old schedule) prior to the new recommendation (Oct. 24, 2024), no additional doses are required.

• #1 Ask The Experts About Vaccines: Meningococcal B | Immunize.org

  https://www.immunize.org/ask-experts/topic/menb/

  ACIP recommends booster doses of MenB vaccines for people at increased risk of MenB disease. Booster doses should be administered to people in the following groups as long as increased risk remains: People with functional or anatomic asplenia, including sickle cell disease, People with persistent complement component deficiency (an immune system disorder), People who take a complement inhibitor (examples include eculizumab [Soliris], ravulizumab [Ultomiris], and sutimlimab [Enjaymo]), Microbiologists who routinely work with meningococcal isolates, Previously vaccinated people who are at risk during a meningococcal B disease outbreak. […] In August 2024, FDA changed the dosing interval for a 2-dose series of Bexsero (MenB-4C, GSK) from 1 month to 6 months, and recommends that people who receive a second dose of Bexsero less than 6 months after dose 1 receive a third dose at least 6 months after dose 1 and at least 4 months after dose 2. However, no additional primary series doses are recommended for people who previously completed the 2-dose series with the shorter interval, in accordance with the licensed and recommended Bexsero schedule at the time.

• #1 MenB vaccine – NHS

  https://www.nhs.uk/vaccinations/menb-vaccine/

  The MenB vaccine helps protect against meningococcal group B bacteria that can cause serious illnesses, including meningitis and sepsis. It’s given to children when they’re 8 weeks, 16 weeks and 1 year old. […] The MenB vaccine helps protect children against bacterial infections caused by meningococcal group B bacteria (MenB). […] Children are offered 3 doses of the MenB vaccine as part of the NHS vaccination schedule. […] It’s best to have the MenB vaccines on time so children are protected when they’re most at risk of getting MenB illnesses. […] Most children can have the MenB vaccine. […] Your child can have the MenB vaccine if they’re unwell but they do not have a high temperature. […] There is 1 type of MenB vaccine routinely given to children in the UK. […] Your GP surgery will usually contact you about your child’s MenB vaccinations.

• #1 Meningitis B (MenB) Vaccine | Fleet Street Clinic, London

  https://fleetstreetclinic.com/services/wellness-vaccinations/meningitis-b/

  Meningitis B vaccination […] Meningitis B is most common in babies under 1, but can affect anyone. Whilst the infection is treatable, it can be fatal in about 1 in 10 cases. The meningitis B vaccine represents a major technological breakthrough: for many years, it seemed that a vaccine against B strains of meningitis would be too difficult to produce. […] […] The meningitis B vaccine is recommended for babies. It is usually given to babies at 8 and 16 weeks, with a booster at 1 year. The vaccine is also recommended for people with some long-term health conditions who are at greater risk of serious health complications following a meningitis infection. […] […] Children aged 2 to 10 years require 2 vaccine doses with at least a 2-month interval between the doses. Adults and Adolescents (from 11 years) require 2 vaccine doses with at least a 1-month interval between the doses. […]

• #1 MenB vaccine – NHS

  https://www.nhs.uk/vaccinations/menb-vaccine/

  Like all medicines, the MenB vaccine can cause side effects, but not all children get them. […] Common side effects of the MenB vaccine include: swelling or pain where the injection was given, a high temperature, feeling tired or irritable, loss of appetite, diarrhoea. […] To help prevent or treat a high temperature, it’s recommended you give your baby child’s paracetamol after their MenB vaccinations at 8 weeks and 16 weeks old. […] The MenB vaccine works very well at protecting children against most types of meningococcal group B bacteria in the UK. […] Research has shown that the vaccine is very effective at preventing illnesses caused by these bacteria. […] Since the vaccine has been used in the UK, there has been a big drop in the number of young children getting MenB illnesses.

• #1 What to Know About the Meningitis B Vaccine

  https://www.healthline.com/health/meningitis/meningitis-b-vaccine

  The meningitis B vaccine can help reduce transmission between people and prevent or manage outbreaks. […] In the United States, two types of meningitis B vaccines are Food and Drug Administration (FDA)-approved Bexsero and Trumenba. […] To receive FDA approval, both vaccines had to undergo clinical trials showing their safety and effectiveness. […] The CDC recommends the meningitis B vaccine for people 10 years or older who are at an increased risk for meningococcal disease. […] A 2021 study examined Bexsero using data from Quebec, Italy, the United Kingdom, Portugal, and South Australia to determine its safety and effectiveness. […] The vaccines were found to be 79 to 100 percent effective in people who received two or more doses. […] In the same 2021 study mentioned above, researchers found the vaccine demonstrated an acceptable level of safety. […] Meningitis B vaccines protect against a potentially life threatening bacterial infection that targets the lining of your brain and spinal cord. […] At this time, meningitis B vaccines are only recommended for people an increase chance of developing meningitis B.

• #1

  https://www.gov.uk/government/news/new-study-confirms-success-of-menb-vaccine-in-the-uk

  MenB vaccination programme has reduced cases of meningitis and septicaemia in young children by almost two-thirds. […] A new study by Public Health England (PHE) shows that infant vaccination against group B meningococcal disease (MenB) has resulted in a significant decline in cases of the disease in young children since the programme was introduced. […] In September 2015, the UK became the first country to offer a new vaccine (Bexsero) against MenB to babies at 8 and 16 weeks of age, followed by a booster around their first birthday. […] PHEs study shows that by the third year of the programme, cases of MenB disease were 62% lower in children who were eligible for at least 2 doses of the vaccine. […] The implementation of the MenB vaccine in 2015 is a great success, it is already saving lives and means fewer parents and young children will experience this devastating illness.

• #1 A physician’s guide to the 2-dose schedule of MenB-FHbp vaccine

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6930067/

  Meningococcal serogroup B (MenB) is the predominant cause of invasive meningococcal disease in the United States, with older adolescents and young adults attending college at increased risk. Notably, MenB caused all meningococcal disease outbreaks at US colleges between 2011 and 2018. MenB disease is vaccine-preventable. The MenB-FHbp vaccine can be administered on a 2-dose (0 and 6 months) schedule to healthy adolescents and young adults or as a tailored 3-dose (0, 12, and 6 months) schedule for individuals at increased risk. […] This review focuses on the 2-dose schedule (0 and 6 months) of MenB-FHbp. Clinical evidence demonstrating strong and broadly protective immunogenicity in adolescents after primary vaccination, immune persistence up to 48 months post-primary vaccination (1861% of subjects across schedules), and immune memory evidenced by robust response to a single booster dose are described.

• #1

  https://www.gov.uk/government/news/new-study-confirms-success-of-menb-vaccine-in-the-uk

  Everyone who knows about this deadly disease and its after effects will welcome the news that the MenB vaccination has reduced cases and saved lives. […] What this latest news shows is that vaccines save lives. […] In England, MenB vaccinations are well-accepted by parents. […] So far, almost 5 million doses of the MenB vaccine have been safely given to children in the UK. […] The MenB vaccine does not protect against all causes of meningitis and septicaemia, so parents need to remain vigilant of the signs and symptoms and seek medical advice if they are concerned. […] The vaccine BEXSERO aims to protect between 73 to 88% of MenB strains causing invasive disease such as meningitis and septicaemia in the UK. […] PHE have reported on the safety of the vaccine after 3 million doses and found no significant safety concerns after widespread use of BEXSERO in UK infants.

• #1 Meningitis B Vaccine | BEXSERO

  https://www.bexsero.com/

  BEXSERO is a vaccine approved for 10- through 25-year-olds to prevent meningococcal group B disease (also known as meningitis B) caused by Neisseria meningitidis bacteria. […] Vaccination with BEXSERO can be completed with 2 or 3 doses. […] Talk to your healthcare professional about vaccination with BEXSERO. […] BEXSERO is a vaccine approved to help prevent meningitis B. […] Anyone who is allergic to the ingredients of BEXSERO or who had a severe allergic reaction after a previous dose should not receive BEXSERO. […] BEXSERO may not protect all vaccine recipients. […] Some individuals with weakened immune systems may have reduced immune responses to BEXSERO. […] Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis group B even after being vaccinated with BEXSERO. […] Ask your healthcare provider about the risks and benefits of BEXSERO. Only a healthcare provider can decide if BEXSERO is right for you or your child.

• #1 FAQs on the MenB vaccine (Bexsero) | Meningitis Now

  https://www.meningitisnow.org/meningitis-explained/meningitis-vaccines/faqs-on-the-menb-vaccine-bexsero/

  The MenB vaccine helps to protect against disease caused by meningococcal group B (MenB) bacteria. MenB is the most common cause of bacterial meningitis in the UK. The vaccine used in the NHS routine immunisation schedule is called Bexsero and made by the pharmaceutical company GSK. […] The MenB vaccine has been offered to babies born on or after 1st May 2015. Most people born before this date will not have been offered the MenB vaccine through the NHS routine immunisation schedule. It is also recommended for people with certain long-term health conditions who are at greater risk. These include individuals with no spleen, or a spleen that does not work properly, sickle cell anaemia, coeliac disease and complement disorders (an immune disorder). […] Since the introduction of this vaccine in 2015, cases of MenB disease have reduced by half in babies. The MenB vaccine also offers some protection against other strains of meningococcal disease, including MenW.

• #1 Meningococcal B vaccine – what you need to know: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/007659.htm

  Soreness, redness, or swelling where the shot is given, tiredness, headache, muscle or joint pain, fever, or nausea can happen after meningococcal B vaccination. Some of these reactions occur in more than half of the people who receive the vaccine. […] An allergic reaction could occur after the vaccinated person leaves the clinic. If you see signs of a severe allergic reaction (hives, swelling of the face and throat, difficulty breathing, a fast heartbeat, dizziness, or weakness), call 9-1-1 and get the person to the nearest hospital.

• #1 Meningococcal Group B Vaccine Side Effects: Common, Severe, Long Term

  https://www.drugs.com/sfx/meningococcal-group-b-vaccine-side-effects.html

  You should not receive the vaccine a second time if you had a life threatening allergic reaction after the first shot. […] Becoming infected with meningococcal disease and developing meningitis is much more dangerous to your health than receiving this vaccine. Any vaccine may cause side effects but the risk of serious side effects is low. […] The most common adverse events were injection site pain, fever, headache, fatigue and myalgia. […] Severe nausea was classified as nausea that resulted in patients unable to perform normal, daily activity. […] Severe arthralgia and severe myalgia were classified as conditions that resulted in patients unable to perform normal, daily activity. […] Severe headache was classified as headache that resulted in patients unable to perform normal, daily activity.

• #1 Arm Pain After a Meningitis Shot: Causes, Remedies, and Legal Options

  https://www.myvaccinelawyer.com/vaccine-injury-lawyer/resources/vaccine/injury/meningitis/arm-pain

  Arm pain is common following the administration of meningococcal vaccines, as the Centers for Disease Control and Prevention (CDC) confirms. […] When the meningitis vaccine is administered, the body recognizes its components as foreign and promptly initiates an immune response, which can result in pain at the injection site. […] Post-meningococcal vaccines, alleviating arm pain likely involves a combination of home remedies and potential medical interventions, ensuring comfort and reducing any adverse impact on daily activities. […] Should arm pain persist or escalate, contacting your doctor becomes imperative for exploring additional treatment options and potentially prescribing alternative medications. […] A vast majority might also experience a phase of muscle pain in the arm, which, under routine circumstances, gradually goes away without intervention.

• #1 MenB Information | Student Affairs and Campus Diversity | SDSU

  https://sacd.sdsu.edu/health-promotion/healthier-you/menb

  San Diego State University is continuing its efforts to support the health and safety of the university community. […] SDSU is asking all students 23 years of age and younger to check their immunization records and to get vaccinated for MenB a potentially fatal disease spread through close contact with those who are ill. […] The effective vaccines for MenB are Trumenba and Bexsero, which were approved by the FDA in 2014-15. […] MenB is life-threatening. Prompt diagnosis and treatment is critical because the disease progresses rapidly and can be fatal in as few as 12 hours after symptoms that often resemble influenza. […] The best prevention is vaccination. The two vaccines that are most effective against MenB are Bexsero and Trumenba. […] All San Diego State University undergraduate students ages 23 and younger who have not been fully immunized with the meningococcal B (MenB) vaccine are urged to get vaccinated as soon as possible.

• #1

  https://www.masta-travel-health.com/Factsheet/Meningitis%20B

  Two meningitis B vaccines are available from MASTA, Bexsero and Trumenba (Trumenba is only for individuals from 10 years of age). […] Bacterial meningitis requires urgent treatment (antibiotics and fluids) in hospital. Without early treatment it can be fatal within hours. […] Men B is a new vaccine, so the need for boosters/further boosters in some age groups has not yet been established (studies are ongoing).

• #1 Immunizations: Meningococcal Vaccines | Wisconsin Department of Health Services

  https://www.dhs.wisconsin.gov/immunization/meningvaccines.htm

  Doctors treat meningococcal disease with antibiotics. It is important that treatment start as soon as possible. Antibiotics help reduce the risk of dying. […] The MenB vaccine prevents infection with meningococcal type B. The CDC recommends a MenB vaccine for people ages 16-23 years old, especially those at high risk of meningococcal disease. Multiple doses of MenB are needed for the best protection. Brand names for the MenB vaccine differ by manufacturer. All doses need to be from the same brand of vaccine.

• #1 Meningitis B: Symptoms, causes, treatment, and prevention

  https://www.medicalnewstoday.com/articles/meningitis-b

  A sore arm is most common and usually only lasts a couple of days. […] Other side effects include swelling at the injection site, fatigue, headache, muscle or joint pain, fever, chills, nausea, diarrhea. […] Following treatment, those with bacterial meningitis will experience relief after 48-72 hours. […] However, they are more likely to develop complications than those who experienced only mild illness. […] Severe infections may cause long-term complications. If this occurs, a person may require medication, supportive care, and long-term therapy. […] Meningitis B is considered a medical emergency, and a doctor will quickly recommend antibiotics for treatment.

• #1 Meningococcal vaccines: Canadian Immunization Guide – Canada.ca

  https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-13-meningococcal-vaccine.html

  Meningococcal vaccine is also recommended for most close contacts of a case of IMD and for outbreak control, if the disease is caused by a serogroup contained in the vaccine. […] For individuals at high risk of developing meningococcal disease due to underlying medical conditions, refer to High risk individuals, Underlying medical conditions. Re-vaccination with Men-C-ACYW is recommended every 3 to 5 years for those vaccinated at 6 years of age and younger and every 5 years for those vaccinated at 7 years of age and older. […] Vaccination or re-vaccination of certain close contacts should be considered in addition to chemoprophylaxis when the serogroup is vaccine preventable, as it may further reduce the risk of subsequent meningococcal disease. […] Consultation with public health officials, experts in communicable disease, or both is important in the assessment and control of meningococcal disease outbreaks. Outbreaks may be controlled by the use of meningococcal vaccines.

• #1 Vaccination Requirements | ULTOMIRIS® (ravulizumab-cwvz) | gMG

  https://ultomirishcp.com/gmg/vaccination-requirements

  If urgent ULTOMIRIS therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible. […] The benefits and risks of antibiotic prophylaxis for prevention of meningococcal infections in patients receiving ULTOMIRIS have not been established.

• #1 Adult Meningococcal Vaccine: Guidelines, Side Effects, Benefits

  https://www.webmd.com/vaccines/meningococcal-vaccine-for-adults

  The meningococcal vaccine protects you from four types of bacteria that cause meningococcal disease. This illness can cause meningitis, an infection of the lining around the brain or spinal cord. It can also cause a blood infection (meningococcal bacteremia), pneumonia, and other problems. Ten percent to 15% of people who are infected with the disease die from it, even if they were treated with antibiotics. As many as 20% of those who survive may have lasting problems such as hearing loss, brain damage, seizures, or loss of limbs. […] For adults at risk, the vaccine is important. […] The CDC recommends you get the vaccine if you are an adult and: […] Some adults may need another type of meningitis vaccine, the serogroup B meningococcal vaccine, if they are exposed to this virus through work or travel or if they have a damaged or missing spleen, or certain immune system disorders.

• #1 What to Know About the Meningitis B Vaccine

  https://www.healthline.com/health/meningitis/meningitis-b-vaccine

  The meningitis B vaccine is a shot thats designed to protect you from developing this illness. Meningitis B is a serious bacterial infection that affects the lining of your brain and spinal cord. It can spread quickly and even be fatal within as little as 24 to 48 hours after symptoms begin. […] The meningitis B vaccine is made from proteins found on the outer part of the MenB bacterium. The exact proteins depend on which version of the vaccine you receive. Being exposed to these proteins stimulates your immune system to recognize the bacterium and teaches your body to protect itself from them. […] The mortality rate from meningitis B in the United States is about 10 to 15 percent when treated and up to 50 percent when untreated. Its also possible to develop long-term conditions such as hearing loss or even brain damage after recovering from meningitis B.

• #1 Preventing Meningococcal Infection in Teens | Allegro Pediatrics

  https://www.allegropediatrics.com/blog/preventing-meningococcal-infection-in-teens

  Meningococcal infection is uncommon; however, it can cause serious illness in healthy adolescents and young adults. […] Fortunately, two meningococcal vaccines, Men ACWY and Men B, are available and protect against different types of meningococcal bacteria. […] Men B vaccine is important for all individuals ages 16-23, especially those will be, or are already, attending college or living in communal housing. […] The Men B vaccine is effective at preventing serious infection. Greater than 80% of adolescents and young adults have strong antibody responses following the 2-dose series. […] Men B vaccine is safe and may be given at the same time as Men ACWY and any other routine vaccinations. […] Currently, both Men ACWY and Men B vaccines for all patients 18 years and younger in the state of Washington are covered either by their insurance or by the Vaccines for Children program.

• #2 GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age | GSK

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-meningitis-b-vaccine-bexsero-receives-breakthrough-therapy-designation-from-us-fda-for-prevention-of-invasive-meningococcal-disease-in-children-2-10-years-of-age/

  GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its meningitis B vaccine Bexsero for the development of the vaccine in the prevention of Invasive Meningococcal Disease (IMD) caused by serogroup B in children 2-10 years of age. […] Bexsero is the first vaccine in the world to receive the Breakthrough Therapy Designation (BTD) twice. […] This designation emphasises the importance of tackling big scientific challenges like meningitis B and breaking new ground in disease prevention through approaches like reverse vaccinology. […] Thirty-five percent of all meningitis B cases in the US occur in children under 11 years old. This designation is an important step forward in meningococcal prevention and extending the protection provided by this vaccine to a vulnerable age group in the US.

• #2 What to Know About the Meningitis B Vaccine

  https://www.healthline.com/health/meningitis/meningitis-b-vaccine

  The meningitis B vaccine is a shot thats designed to protect you from developing this illness. Meningitis B is a serious bacterial infection that affects the lining of your brain and spinal cord. It can spread quickly and even be fatal within as little as 24 to 48 hours after symptoms begin. […] The meningitis B vaccine is made from proteins found on the outer part of the MenB bacterium. The exact proteins depend on which version of the vaccine you receive. Being exposed to these proteins stimulates your immune system to recognize the bacterium and teaches your body to protect itself from them. […] The mortality rate from meningitis B in the United States is about 10 to 15 percent when treated and up to 50 percent when untreated. Its also possible to develop long-term conditions such as hearing loss or even brain damage after recovering from meningitis B.

• #2 MenB Information | Student Affairs and Campus Diversity | SDSU

  https://sacd.sdsu.edu/health-promotion/healthier-you/menb

  San Diego State University is continuing its efforts to support the health and safety of the university community. […] SDSU is asking all students 23 years of age and younger to check their immunization records and to get vaccinated for MenB a potentially fatal disease spread through close contact with those who are ill. […] The effective vaccines for MenB are Trumenba and Bexsero, which were approved by the FDA in 2014-15. […] MenB is life-threatening. Prompt diagnosis and treatment is critical because the disease progresses rapidly and can be fatal in as few as 12 hours after symptoms that often resemble influenza. […] The best prevention is vaccination. The two vaccines that are most effective against MenB are Bexsero and Trumenba. […] All San Diego State University undergraduate students ages 23 and younger who have not been fully immunized with the meningococcal B (MenB) vaccine are urged to get vaccinated as soon as possible.

• #2 GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age | GSK

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-meningitis-b-vaccine-bexsero-receives-breakthrough-therapy-designation-from-us-fda-for-prevention-of-invasive-meningococcal-disease-in-children-2-10-years-of-age/

  Invasive meningococcal B disease is the leading cause of life-threatening meningitis in the industrialised world. […] Bexsero is licensed in more than 35 countries, including the U.S. […] In the U.S., Bexsero is approved for use in individuals from 10 years through 25 years of age. […] In Brazil, Bexsero is approved for use in individuals from two months to 50 years of age. […] In the US, the vaccine is currently licensed for adolescents (11 years of age) and adults. […] Vaccination with Bexsero may not provide protection against all meningococcal serogroup B strains. […] Vaccination with Bexsero may not result in protection in all vaccine recipients.

• #2 Ask The Experts About Vaccines: Meningococcal B | Immunize.org

  https://www.immunize.org/ask-experts/topic/menb/

  MenB vaccines were approved based on the serologic response to the vaccine. Because meningococcal B disease is so rare, no data are available on vaccine effectiveness against clinical disease or duration of protection against clinical disease. Short term protection refers to the known duration of the antibody response. Available data indicate that protective antibody levels wane in most recipients within 12 years of completion of the primary series. Antibody levels rise sharply within 1-2 weeks of a booster dose. […] MenB is routinely recommended for these groups: People age 10 years and older who have functional or anatomic asplenia (including sickle cell disease), People age 10 years and older who have persistent complement component deficiency (an immune system disorder) or who take a complement inhibitor (examples include eculizumab [Soliris], ravulizumab [Ultomiris], and sutimlimab [Sanofi]), People age 10 years and older who are exposed during an outbreak caused by serogroup B, Microbiologists who work with meningococcal isolates in a laboratory.

• #2 Vaccination Requirements | ULTOMIRIS® (ravulizumab-cwvz) | gMG

  https://ultomirishcp.com/gmg/vaccination-requirements

  Complete or update meningococcal vaccination (for serogroups A, C, W, Y and B) at least 2 weeks prior to administration of the first dose of ULTOMIRIS, per the current ACIP recommendations for patients receiving a complement inhibitor. […] Your patient must receive both MenACWY and MenB vaccine series. The vaccines may be administered during the same visit but at different injection sites. […] To help reduce the risk of meningococcal infections, the complete series for the MenACWY and MenB vaccines should be administered. […] Revaccinate patients in accordance with ACIP recommendations considering the duration of ULTOMIRIS therapy. […] Vaccination does not eliminate the risk of serious meningococcal infections, despite development of antibodies following vaccination. […] Patients receiving ULTOMIRIS are at increased risk for invasive disease caused by Neisseria meningitidis, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious meningococcal infections and evaluate immediately if infection is suspected.

• #2 Meningococcal disease | The Australian Immunisation Handbook

  https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/meningococcal-disease

  Any person from 6 weeks of age who wants to reduce their risk of meningococcal disease is recommended to receive MenACWY vaccine and MenB vaccine. […] Any person who wants to reduce their risk of invasive meningococcal disease can receive MenACWY and MenB vaccines from as early as 6 weeks of age. […] All infants and children aged <2 years are recommended to receive the MenB vaccine. The MenB vaccine used in infants and children aged <2 years is Bexsero, which is currently the only MenB vaccine registered and available in Australia. [...] Healthy adolescents aged 15–19 years are recommended to receive 2 doses of MenB vaccine. [...] Aboriginal and Torres Strait Islander people aged 2 months to 19 years are recommended to receive a course of MenB vaccine. [...] MenACWY and MenB vaccines are funded through the NIP for people with certain medical conditions that increase their risk of invasive meningococcal disease.

• #2 Meningococcemia Treatment & Management: Approach Considerations, Emergency Management of Meningococcal Infection, Pharmacologic Therapy

  https://emedicine.medscape.com/article/221473-treatment

  Specific categories of individuals at high risk for meningococcal disease include the following: Persistent complement component deficiencies, such as C3, C5C9, properdin, factor D, or factor H deficiencies, can increase the risk for meningococcal disease up to 10,000-fold. Patients with complement deficiencies may experience recurrent disease, and inherited disorders within families may also be affected, warranting consideration for testing for complement deficiency in individuals with meningococcal disease. […] The use of complement inhibitors, such as eculizumab (Soliris) and ravulizumab (Ultomiris), is associated with a substantially increased risk for meningococcal disease. Eculizumab use, in particular, has been linked to a significant incidence of meningococcal disease. Therefore, healthcare providers should consider antimicrobial prophylaxis for patients receiving complement inhibitors to mitigate the risk of infection.

• #2 ZILBRYSQ® Vaccination Schedule

  https://www.zilbrysqhcp.com/vaccination

  Complete or update meningococcal vaccination (for serogroups A, C, W, Y, and B) at least 2 weeks prior to administration of the first dose of ZILBRYSQ, according to current ACIP recommendations for patients receiving a complement inhibitor. […] The benefits and risks of antibiotic prophylaxis for prevention of meningococcal infections in patients receiving ZILBRYSQ have not been established. […] ZILBRYSQ, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis. Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. […] Complete or update vaccination for meningococcal bacteria at least 2 weeks prior to the first dose of ZILBRYSQ, unless the risks of delaying therapy outweigh the risk of developing a serious infection.

• #2 Meningococcal Meningitis Treatment & Management: Approach Considerations, Pharmacologic Care, Prophylaxis

  https://emedicine.medscape.com/article/1165557-treatment

  Vaccination is used for close contacts of patients with meningococcal disease due to A, C, Y, or W135 serogroups, to prevent secondary cases. Current meningococcal vaccines are indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis. […] In October 2024, the Advisory Committee on Immunization Practices (ACIP) approved the Recommended Immunization Schedule for Adults Ages 19 Years or Older, United States, 2025. For the MenACWY vaccine, booster doses are advised following the initial series. The updated guidelines now include the revised vaccination schedule for MenB, Bexsero. For routine vaccination, it is recommended that healthy individuals aged 16-23 years receive a 2-dose series, with doses administered 6 months apart, based on shared clinical decision-making. Adults at increased risk for serogroup B meningococcal disease should receive a 3-dose series at intervals of 0, 12, and 6 months. Furthermore, the new recommendations for the use of the MenB vaccine during pregnancy suggest postponing vaccination until after pregnancy, due to insufficient safety data for pregnant individuals.

• #2 HCP Site | TRUMENBA® (Meningococcal Group B Vaccine) | Safety Info

  https://trumenba.pfizerpro.com/

  After the October 2024 ACIP vote, all MenB vaccines now align to the same schedule (2 doses at 0 and 6 months when used as a 2-dose series) for healthy adolescents and young adults aged 16-23 years based on shared clinical decision-making.1,2 TRUMENBA has demonstrated coverage against diverse MenB strains by covering both subfamilies A and B of fHbp. TRUMENBA is proven to help protect against diverse MenB strains, which is important because you don’t know which of the 1800 MenB strains your patients may encounter. TRUMENBA offers proven protection with a 2-dose schedule. ONLY TRUMENBA covers both subfamilies of fHbp, A B, that have been found on 99% of MenB disease-causing strains, as well as strains that have caused MenB outbreaks at US colleges. MenB vaccination is part of the CDC 16-year-old vaccination platform. The Advisory Committee on Immunization Practices (ACIP) recommends 2 doses for persons aged 16 through 23 years who are not at increased risk for meningococcal disease, based on shared clinical decision-making. ACIP recommends 3 doses for persons aged 10 years who are at increased risk. Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age.

• #2 Ask The Experts About Vaccines: Meningococcal B | Immunize.org

  https://www.immunize.org/ask-experts/topic/menb/

  ACIP recommends booster doses of MenB vaccines for people at increased risk of MenB disease. Booster doses should be administered to people in the following groups as long as increased risk remains: People with functional or anatomic asplenia, including sickle cell disease, People with persistent complement component deficiency (an immune system disorder), People who take a complement inhibitor (examples include eculizumab [Soliris], ravulizumab [Ultomiris], and sutimlimab [Enjaymo]), Microbiologists who routinely work with meningococcal isolates, Previously vaccinated people who are at risk during a meningococcal B disease outbreak. […] In August 2024, FDA changed the dosing interval for a 2-dose series of Bexsero (MenB-4C, GSK) from 1 month to 6 months, and recommends that people who receive a second dose of Bexsero less than 6 months after dose 1 receive a third dose at least 6 months after dose 1 and at least 4 months after dose 2. However, no additional primary series doses are recommended for people who previously completed the 2-dose series with the shorter interval, in accordance with the licensed and recommended Bexsero schedule at the time.

• #2 Meningococcal Vaccine Administration | CDC

  https://www.cdc.gov/vaccines/vpd/mening/hcp/administering-vaccine.html

  Administer 2 or 3 doses. Administer 2 doses to healthy adolescents who are not at increased risk for serogroup B meningococcal disease. Administer the second dose 6 months after the first dose. […] Administer 3 doses to people 10 years of age or older who are at increased risk for meningococcal disease. This includes during outbreaks of serogroup B meningococcal disease. Administer the second dose 1 to 2 months after the first dose. Administer the third dose 6 months after the first dose. […] For patients at prolonged increased risk for meningococcal disease, CDC recommends MenB booster doses after completion of the primary series. Administer a booster dose of MenB vaccine 1 year after series completion and then every 2 to 3 years thereafter.

• #2 Meningococcal Vaccines – Medical Clinical Policy Bulletins | Aetna

  https://www.aetna.com/cpb/medical/data/300_399/0356.html

  The ACIP recommends booster doses for previously vaccinated persons who become or remain at increased risk. For persons 10 years of age or older with persistent complement deficiencies (including patients using a complement inhibitor), anatomic and functional asplenia (including sickle cell disease), or are microbiologists routinely exposed to isolates of N. meningitidis, ACIP recommends single booster dose at 1 yr after completion of primary vaccination and every 2-3 yrs thereafter. […] In August 2024, the FDA approved Bexsero 3-dose series (at 0, 1-2, and 6 months) for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B for use in individuals aged 10 through 25 years. Previously approved as a 2-dose series. […] Trumenba is licensed in the United States to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 to 25 years of age.

• #2 Schedule a Meningococcal Vaccine Appointment Today

  https://a-zpeds.com/meningococcal-menacwy-and-menb/

  Meningococcal vaccines, including MenACWY and MenB, protect against meningococcal disease caused by the Neisseria meningitidis bacteria. Meningococcal disease can lead to serious infections such as meningitis (infection of the lining around the brain and spinal cord) and septicemia (bloodstream infection). These infections can develop rapidly and are potentially life-threatening. The MenACWY vaccine covers four serogroups (A, C, W, and Y), while the MenB vaccine protects against serogroup B. […] Ensuring your child is vaccinated with MenACWY and MenB vaccines is vital in protecting them against these potentially deadly infections.

• #2 What to Know About the Meningitis B Vaccine

  https://www.healthline.com/health/meningitis/meningitis-b-vaccine

  The meningitis B vaccine can help reduce transmission between people and prevent or manage outbreaks. […] In the United States, two types of meningitis B vaccines are Food and Drug Administration (FDA)-approved Bexsero and Trumenba. […] To receive FDA approval, both vaccines had to undergo clinical trials showing their safety and effectiveness. […] The CDC recommends the meningitis B vaccine for people 10 years or older who are at an increased risk for meningococcal disease. […] A 2021 study examined Bexsero using data from Quebec, Italy, the United Kingdom, Portugal, and South Australia to determine its safety and effectiveness. […] The vaccines were found to be 79 to 100 percent effective in people who received two or more doses. […] In the same 2021 study mentioned above, researchers found the vaccine demonstrated an acceptable level of safety. […] Meningitis B vaccines protect against a potentially life threatening bacterial infection that targets the lining of your brain and spinal cord. […] At this time, meningitis B vaccines are only recommended for people an increase chance of developing meningitis B.

• #2 Meningitis B (MenB) Vaccine | Fleet Street Clinic, London

  https://fleetstreetclinic.com/services/wellness-vaccinations/meningitis-b/

  The vaccine we use is called 'Bexsero’ and it contains major proteins from group B Neisseria meningitidis bacteria. They work by stimulating the immune system to protect against future exposures to meningococcal bacteria. Bexsero is not a live vaccine. […] […] Meningitis B vaccine is highly effective, providing protection in the range of 85 to 100 percent. In the three years following its introduction in the UK, the overall number of cases of meningitis B in infants fell by 75%. […] […] In infants and children, the most common reaction has been a fever and some swelling around the injection site. Infant paracetamol is sometimes recommended for small children. Our staff will give you advice about any likely side effects during your appointment. […] […] The vaccine is available on the NHS to children born after May 1, 2015. If your child was born before this date, they will not have been offered the vaccine as part of their routine NHS immunisation schedule. You can choose to vaccinate them privately and as with most vaccinations, it is never too late to vaccinate. Unvaccinated people can catch meningitis B at any age. […] […] Meningitis B vaccine protects only against the B strain. Meningitis ACWY vaccine provides protection against the A, C, W-135, and Y strains, and is given separately.

• #2 13. Meningococcal disease – Health New Zealand | Te Whatu Ora

  https://www.tewhatuora.govt.nz/for-health-professionals/clinical-guidance/immunisation-handbook/13-meningococcal-disease

  MenB (Bexsero) is funded as part of the routine childhood Schedule for all infants. […] MenB (Bexsero) and MenACWY (Nimenrix, from age 6 weeks to under 12 months; MenQuadfi from age 12 months) for: patients pre- or post-splenectomy or with functional or anatomical asplenia, patients with HIV, complement deficiency (acquired, including monoclonal antibody therapy against C5, or inherited), pre- or post-solid organ transplant, HSCT (bone marrow transplant) patients, patients prior to planned and following immunosuppression, close contacts of meningococcal cases (any group), patients with prior meningococcal disease of any group. […] MenB: 75% reduction in group B cases in infants over a 3-year period in the UK and cross-protection against group W observed; 71% reduction in group B disease in adolescents.

• #2 Meningitis B: Symptoms, causes, treatment, and prevention

  https://www.medicalnewstoday.com/articles/meningitis-b

  A sore arm is most common and usually only lasts a couple of days. […] Other side effects include swelling at the injection site, fatigue, headache, muscle or joint pain, fever, chills, nausea, diarrhea. […] Following treatment, those with bacterial meningitis will experience relief after 48-72 hours. […] However, they are more likely to develop complications than those who experienced only mild illness. […] Severe infections may cause long-term complications. If this occurs, a person may require medication, supportive care, and long-term therapy. […] Meningitis B is considered a medical emergency, and a doctor will quickly recommend antibiotics for treatment.

• #2 MenB Information | Student Affairs and Campus Diversity | SDSU

  https://sacd.sdsu.edu/health-promotion/healthier-you/menb

  Fully immunized means having received all doses required for the MenB vaccination, a multi-dose series. […] Both MenB vaccines are administered through an intramuscular injection in the arm. […] The Centers for Disease Control and Prevention reports that potential side effects from receiving the MenB vaccine can include soreness, redness and swelling around the area where the shot was given; feeling tired; headaches; muscle or joint pain; fever or chills; nausea or diarrhea. […] If you have started one of the MenB vaccine series (Bexsero or Trumenba), make plans to complete the appropriate series through your health-care provider or a convenient pharmacy at the correct time interval. […] Students may only request medical exemptions. […] Individuals should avoid the vaccine if they have had any severe, life-threatening allergic reaction to a previous dose of MenB vaccine or if they have a severe allergy to any part of this vaccine.

• #2 The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme–New challenges for public health – PubMed

  https://pubmed.ncbi.nlm.nih.gov/26433141/

  The United Kingdom is the first country to introduce Bexsero() (GSK Biologicals), a multicomponent, protein-based vaccine against meningococcal group B (MenB), into the national infant immunisation programme. […] Because of high rates of fever post-vaccination, parents were advised to give their infants three doses of prophylactic paracetamol, with the first dose given as soon as possible after the primary MenB vaccination dose. […] PHE is also conducting detailed clinical and epidemiological surveillance to assess the impact of the MenB immunisation programme on the morbidity and mortality associated with invasive meningococcal disease in infants and young children.

• #2 Meningococcal Group B Vaccine Side Effects: Common, Severe, Long Term

  https://www.drugs.com/sfx/meningococcal-group-b-vaccine-side-effects.html

  Severe fatigue and severe fever were classified as conditions that resulted in patients unable to perform normal, daily activity. […] Meningococcal group B vaccine side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

• #2 Arm Pain After a Meningitis Shot: Causes, Remedies, and Legal Options

  https://www.myvaccinelawyer.com/vaccine-injury-lawyer/resources/vaccine/injury/meningitis/arm-pain

  However, when symptoms persist but exacerbate over weeks or months, it could indicate a relatively rare condition named SIRVA, an acronym for Shoulder Injury Related to Vaccine Administration. […] SIRVA (Shoulder Injury Related to Vaccine Administration) exhibits a distinct set of symptoms, generally emerging within 48 hours following a meningitis shot, each of which signals an immediate need for attention and potential intervention. […] Recognizing the importance of swift diagnosis and treatment is paramount to mitigate potential complications and pave the way for optimal recovery, protecting against developing more serious symptoms. […] The aftermath of a vaccine injury can be both physically and emotionally taxing. […] Seeking compensation with experienced vaccine injury lawyers lets you focus squarely on recovery without the looming shadow of a financial burden, simultaneously safeguarding your health and financial stability. […] Our team of skilled experts at My Vaccine Lawyer specializes in guiding SIRVA cases and provides complimentary case assessments.

• #2 Children Between the Ages of 1 and 9 Are Closer to Having an FDA Approved MenB Vaccine — Vax-Before-Travel

  https://www.vax-before-travel.com/trumenba-receives-breakthrough-therapy-designation-menb-vaccine-protect-children-between-1-and-9

  There is an active clinical study to confirm the effectiveness of the two-dose vaccination schedule. […] IMPORTANT SAFETY INFORMATION: TRUMENBA should not be given to anyone with a history of a severe allergic reaction after a previous dose of TRUMENBA. Some individuals with weakened immune systems may have a reduced immune response. […] As with any vaccine, vaccination with TRUMENBA may not protect all vaccine recipients against N meningitidis group B infections. […] Only a healthcare provider can decide if TRUMENBA is right for you or your child.

• #2 Reasons Not to Get the Meningitis Vaccine: Potential Side Effects – Jeffrey S. Pop & Associates

  https://www.vaccineinjuryteam.com/blog/2024/january/reasons-not-to-get-the-meningitis-vaccine-potent/

  Meningitis vaccine is generally safe. Even so, it may be unsafe for a particular group of people. A healthcare provider often recommends people who are moderately or severely ill wait before getting a meningitis vaccine. […] The meningitis vaccine is linked to several side effects, including an increased risk of Guillain-Barr syndrome (GBS). As such, it is advisable to follow the instructions of a healthcare provider. […] More importantly, your healthcare provider can advise you on ways to prevent or reduce the effects of the meningitis vaccine. […] If youre experiencing a meningitis vaccine reaction or sensitivity and your condition is worsening or persistent, it could be a sign of meningitis vaccine injury. […] There are increasing cases of injuries caused by the meningitis vaccine.

• #2 Meningococcal B

  https://www.hse.ie/eng/health/immunisation/hcpinfo/othervaccines/meningococcalb/

  MenB vaccine has been shown to be very effective at producing an immune response to the particular strains of meningococcal B causing invasive meningococcal disease in Ireland. Research has suggested that up to 88% of meningococcal B strains should be protected by MenB vaccine. […] MenB vaccine should be given to cases and all previously unimmunised close contacts of a case of any age and to control outbreaks of meningococcal disease as agreed by the Department of Public Health and the Health Protection Surveillance Centre. […] MenB vaccine is indicated for individuals from 2 months and older. There is no upper age limit. The minimum age at which Bexsero can be given is 6 weeks. […] Yes. There is no evidence of risk from vaccinating pregnant women with inactivated bacterial vaccines so MenB vaccine can be given to pregnant women. […] Yes. There is no evidence of risk from vaccinating breastfeeding mothers with inactivated bacterial vaccines so MenB vaccine can be given to breastfeeding mothers.

• #2 Risks and Side Effects | BEXSERO

  https://www.bexsero.com/risks-and-side-effects/

  BEXSERO is a vaccine approved for 10- through 25-year-olds to prevent meningococcal group B disease (also known as meningitis B) caused by Neisseria meningitidis bacteria. […] BEXSERO may not protect all vaccine recipients. […] Vaccination with BEXSERO may not result in protection in all vaccine recipients. […] Some individuals with weakened immune systems may have reduced immune responses to BEXSERO. […] Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis group B even after being vaccinated with BEXSERO. […] The most common side effects associated with BEXSERO are: pain, redness, or swelling at the injection site; fatigue; headache; nausea; muscle pain. […] Ask your healthcare provider about the risks and benefits of BEXSERO. Only a healthcare provider can decide if BEXSERO is right for you or your child.

• #2 Immunizations: Meningococcal Vaccines | Wisconsin Department of Health Services

  https://www.dhs.wisconsin.gov/immunization/meningvaccines.htm

  Doctors treat meningococcal disease with antibiotics. It is important that treatment start as soon as possible. Antibiotics help reduce the risk of dying. […] The MenB vaccine prevents infection with meningococcal type B. The CDC recommends a MenB vaccine for people ages 16-23 years old, especially those at high risk of meningococcal disease. Multiple doses of MenB are needed for the best protection. Brand names for the MenB vaccine differ by manufacturer. All doses need to be from the same brand of vaccine.

• #2 Meningitis B: Symptoms, causes, treatment, and prevention

  https://www.medicalnewstoday.com/articles/meningitis-b

  Meningitis B is a medical emergency, and healthcare professionals will treat it as soon as possible using antibiotics. […] Doctors may also treat those in contact with someone with meningitis B as a preventative measure. […] Meningitis B vaccines include Bexsero and Trumenba. […] Those aged 16-23 years can get the MenB vaccine, as well as those who are at an increased risk of meningococcal disease, including: those at risk due to an outbreak, those who have a damaged spleen or those without a spleen, including those with sickle cell disease, those with complement component deficiency, which is a rare condition that affects the immune system, those taking complement inhibitor drugs, such as eculizumab or ravulizumab, microbiologists who work with N. meningitidis. […] The side effects of meningococcal vaccines are mild and present in more than half of those who are vaccinated.

• #2 Meningococcemia Treatment & Management: Approach Considerations, Emergency Management of Meningococcal Infection, Pharmacologic Therapy

  https://emedicine.medscape.com/article/221473-treatment

  ACIP recommends MenB vaccination for individuals aged 10 years and older who are at increased risk, with boosters 1 year after completing the primary series, then every 2-3 years. […] The preferred age for MenB vaccination is 16-18. Booster doses are not recommended unless the individual becomes at increased risk. Booster doses are recommended for previously vaccinated individuals at continued risk. […] Meningococcal disease can be prevented by vaccination with group-specific meningococcal capsular polysaccharides.

• #2 ZILBRYSQ® Vaccination Schedule

  https://www.zilbrysqhcp.com/vaccination

  Patients receiving ZILBRYSQ are at increased risk for invasive disease caused by Neisseria meningitidis, even if they develop antibodies following vaccination. […] Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection is suspected.

• #2 Children Between the Ages of 1 and 9 Are Closer to Having an FDA Approved MenB Vaccine — Vax-Before-Travel

  https://www.vax-before-travel.com/trumenba-receives-breakthrough-therapy-designation-menb-vaccine-protect-children-between-1-and-9

  A Meningococcal Group B Vaccine named Trumenba has received the first and only Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for active immunization to prevent invasive disease caused by Neisseria meningitidis group B (MenB) in children ages 1 through 9 years. […] Vaccination is the most effective way to protect against this aggressive disease that has a narrow timeframe for diagnosis and treatment, says the Centers for Disease Control and Prevention (CDC). […] As required to assess the safety and effectiveness of Trumenba in children age 1 to 9 years of age, Pfizer successfully completed Phase 2 studies in this investigational age group and these data have been submitted to the FDA. […] Currently, TRUMENBA can be administered as a two or three-dose schedule to adolescents and young adults 10 through 25 years of age depending on an individual’s risk of exposure and susceptibility to MenB.

• #2

  https://www.gov.uk/government/news/new-study-confirms-success-of-menb-vaccine-in-the-uk

  Everyone who knows about this deadly disease and its after effects will welcome the news that the MenB vaccination has reduced cases and saved lives. […] What this latest news shows is that vaccines save lives. […] In England, MenB vaccinations are well-accepted by parents. […] So far, almost 5 million doses of the MenB vaccine have been safely given to children in the UK. […] The MenB vaccine does not protect against all causes of meningitis and septicaemia, so parents need to remain vigilant of the signs and symptoms and seek medical advice if they are concerned. […] The vaccine BEXSERO aims to protect between 73 to 88% of MenB strains causing invasive disease such as meningitis and septicaemia in the UK. […] PHE have reported on the safety of the vaccine after 3 million doses and found no significant safety concerns after widespread use of BEXSERO in UK infants.

• #2 Why isn’t the MenB vaccine recommended for everyone? – Sharecare

  https://www.sharecare.com/vaccinations-immunizations/understanding-menb-vaccine-recommendation

  The MenB vaccine may help protect against serogroup B. The CDC recommends that patients and healthcare providers decide together whether to get it. […] For most healthy teens, it is optional, though the CDC recommends it for some high-risk groups, as well as those at risk due to a local outbreak. […] Given the potentially devastating effects of meningococcal disease, a person may wonder why MenB vaccination is not more widely recommended. The answer to this question has a lot to do with the need for more information before health experts can recommend routine MenB vaccination. […] Health experts are always working to design tools and provide recommendations that could help people avoid serious illness. […] While blood tests in studies show that the MenB vaccine boosts immunity in people, evaluating how many infections the vaccine will prevent in real-world settings takes many years of data.

• #3 FAQs on the MenB vaccine (Bexsero) | Meningitis Now

  https://www.meningitisnow.org/meningitis-explained/meningitis-vaccines/faqs-on-the-menb-vaccine-bexsero/

  Babies receive three doses: at 2 and 4 months and a booster at 12 months of age. Anyone receiving the vaccine over the age of 2 years only requires 2 doses. […] No, the MenB vaccine is not a live vaccine and cannot cause meningitis. […] High rates of fever have been reported in infants receiving the MenB vaccine with their other routine immunisations. Use of paracetamol has been advised for infants at the time of immunisation, to prevent fever. […] Another MenB vaccine, called Trumenba, has recently been licenced for use in Europe and the UK. This vaccine has been developed by Pfizer and is licenced for use in adults and children over the age of 10. This vaccine is available through private providers.

Zobacz więcej